Patents by Inventor Peter Wilhelm Gout

Peter Wilhelm Gout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
    Patent number: 9790500
    Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: October 17, 2017
    Inventors: Yuzhuo Wang, Hui Xue, Sze Ue Luk, Peter Wilhelm Gout, Martin E. Gleave, Colin C. Collins
  • DUAL TARGETING ANTISENSE OLIGONUCLEOTIDES AS APOPTOTIC INHIBTOR THERAPEUTIC COMPOSTIONS AND METHODS FOR THEIR USE IN THE TREATMENT OF CANCER
    Publication number: 20170015997
    Abstract: Provided herein are compositions, method and uses for modulating IAP activity or for the treatment of cancer. The compositions comprise dual-targeting antisense oligonucleotides (dASO) for administration to a cancer cell, wherein the cancer cell may be characterized by elevated expression of one of more of BIRC6, cIAP1 or survivin. The cancer may be selected from one or more of: prostate cancer; childhood de novo acute myeloid leukemia; colorectal cancer; neuroblastoma; melanoma; and non-small cell lung cancer. The prostate cancer may be castration-resistant prostate cancer (CRPC).
    Type: Application
    Filed: July 15, 2016
    Publication date: January 19, 2017
    Inventors: Yuzhuo Wang, Hui Xue, Sze Ue Luk, Peter Wilhelm Gout, Martin E. Gleave, Colin C. Collins
  • Use of n-heterocyclic substituted salicylates for inhibition of cellular uptake of cystine
    Publication number: 20030186950
    Abstract: A method is provided for inhibiting cellular uptake of cystine with a N-heterocyclic substituted salicylate for treatment such as sulfasalazine: Also provided we uses of a N-heterocyclic substituted Salicylate of cancer, for inhibition of cellular uptake of cystine, and for preparation of medicaments for the treatment of cancer or for inhibiting the cellular uptake of cystine. Preferably, the cancer is one which is dependent upon extracellular cystine or cysteine. Also provided are liposomal formulations of N-heterocyclic substituted salicylates.
    Type: Application
    Filed: October 23, 2002
    Publication date: October 2, 2003
    Inventors: Peter Wilhelm Gout, Nicholas Bruchovsky